RU2006124794A - Применение цис-гидроксипролина в качестве ингибитора ключевых мишеней - Google Patents
Применение цис-гидроксипролина в качестве ингибитора ключевых мишеней Download PDFInfo
- Publication number
- RU2006124794A RU2006124794A RU2006124794/15A RU2006124794A RU2006124794A RU 2006124794 A RU2006124794 A RU 2006124794A RU 2006124794/15 A RU2006124794/15 A RU 2006124794/15A RU 2006124794 A RU2006124794 A RU 2006124794A RU 2006124794 A RU2006124794 A RU 2006124794A
- Authority
- RU
- Russia
- Prior art keywords
- cis
- hydroxyproline
- use according
- inhibitor
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pyrrole Compounds (AREA)
Claims (11)
1. Применение цис-гидроксипролина для ингибирования ключевых мишеней, выбранных из группы, включающей коллаген IV и глутатион-S-трансферазу (GST).
2. Применение по п.1, при котором ингибирование осуществляют in vitro или in vivo.
3. Применение по п.1 или 2, при котором цис-гидроксипролин используется в виде геля, пудры, порошка, таблетки, таблетки с продленным высвобождением, премикса, эмульсии, состава для заваривания, инфузионного раствора, капель, концентрата, гранулята, сиропа, пилюль, болюса, капсулы, аэрозоля, распыляемого состава и/или состава для ингаляции.
4. Применение по п.1, при котором цис-гидроксипролин содержится в составе в концентрации от 0,1 до 99,5, предпочтительно от 0,5 до 95 и более предпочтительно от 1 до 80 вес.%.
5. Применение по п.1, при котором используют растворы для инфузии, содержащие 1-2 вес.% цис-гидроксипролина.
6. Применение по п.1, при котором цис-гидроксипролин применяют в количестве от 0,05 до 1000 мг/кг веса, предпочтительно от 5 до 450 мг/кг веса в сутки.
7. Способ ингибирования глутатион-S-трансферазы и/или коллагена IV в in vivo или in vitro системе, характеризующийся тем, что система контактирует с цис-гидроксипролином.
8. Способ по п.7, при котором контактирование в случае in vivo систем осуществляют перорально, вагинально, ректально, назально, подкожно, внутривенно, внутримышечно, регионально, внутрибрюшинно и/или локально.
9. Ингибитор коллагена-IV и/или GST, включающий цис-гидроксипролин, возможно, вместе с фармацевтически приемлемым носителем.
10. Ингибитор по п.9, у которого носитель выбран из группы, включающей наполнители, разбавители, связующие, увлажнители, дезинтегранты, замедлители растворения, ускорители абсорбции, смачивающие агенты, адсорбенты и/или смазывающие агенты.
11. Ингибитор по п.9 или 10, у которого носители представляют собой липосомы, сиосомы и/или ниосомы.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10359829A DE10359829A1 (de) | 2003-12-12 | 2003-12-12 | Verwendung von CHP als Inhibitor von Glutathion-S-Transferasen und Kollagen IV |
| DE10359829.4 | 2003-12-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006124794A true RU2006124794A (ru) | 2008-01-20 |
Family
ID=34672935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006124794/15A RU2006124794A (ru) | 2003-12-12 | 2004-12-13 | Применение цис-гидроксипролина в качестве ингибитора ключевых мишеней |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20070099982A1 (ru) |
| EP (1) | EP1701720A1 (ru) |
| JP (1) | JP2007513895A (ru) |
| CN (1) | CN1889945A (ru) |
| AU (1) | AU2004296131A1 (ru) |
| BR (1) | BRPI0417542A (ru) |
| CA (1) | CA2548443A1 (ru) |
| DE (1) | DE10359829A1 (ru) |
| RU (1) | RU2006124794A (ru) |
| WO (1) | WO2005056006A1 (ru) |
| ZA (1) | ZA200605706B (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2529860C2 (ru) * | 2009-01-30 | 2014-10-10 | Тояма Кемикал Ко., Лтд. | Производное n-ацилантраниловой кислоты или его соль |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10328051B2 (en) * | 2014-09-22 | 2019-06-25 | Zoser B. Salama | Proline or proline derivatives for the treatment of dementia |
| WO2022192899A1 (en) * | 2021-03-11 | 2022-09-15 | Lapix Therapeutics, Inc. | Compositions and methods for reducing immune intolerance |
| CA3228242A1 (en) | 2021-08-13 | 2023-02-16 | Anas M. Fathallah | Compositions and methods for reducing immune intolerance and treating autoimmune disorders |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1281288C (en) * | 1984-11-05 | 1991-03-12 | Wilhelm Hoerrmann | Tumor therapy |
| US6153643A (en) * | 1984-11-05 | 2000-11-28 | Hoerrmann; Wilhelm | Anti-cancer-substance |
| US5665371A (en) * | 1985-05-20 | 1997-09-09 | Hoerrmann; Wilhelm | Medicines which contain derivatives of proline or hydroxyproline |
| DE3518078A1 (de) * | 1985-05-20 | 1986-11-20 | Wilhelm Dr. 8127 Iffeldorf Hoerrmann | Arzneimittel, die derivate des prolin oder hydroxyprolin enthalten |
| JPS6388136A (ja) * | 1986-09-30 | 1988-04-19 | Advance Co Ltd | 発癌予防剤 |
| US5091171B2 (en) * | 1986-12-23 | 1997-07-15 | Tristrata Inc | Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use |
| US5372807A (en) * | 1990-05-14 | 1994-12-13 | University Of Medicine And Dentistry Of New Jersey | Polymers containing antifibrotic agents, compositions containing such polymers, and methods of preparation and use |
| AU2380097A (en) * | 1996-03-11 | 1997-10-01 | Wilhelm Hoerrmann | Combination of cis-4-hydroxy-l-proline and n-methyl-cis-4-hydroxy-l-proline for use as a therapeutic agent, in particular in cancer treatment |
| US6420378B1 (en) * | 1999-10-15 | 2002-07-16 | Supergen, Inc. | Inhibition of abnormal cell proliferation with camptothecin and combinations including the same |
-
2003
- 2003-12-12 DE DE10359829A patent/DE10359829A1/de not_active Withdrawn
-
2004
- 2004-12-13 BR BRPI0417542-5A patent/BRPI0417542A/pt not_active IP Right Cessation
- 2004-12-13 AU AU2004296131A patent/AU2004296131A1/en not_active Abandoned
- 2004-12-13 US US10/596,410 patent/US20070099982A1/en not_active Abandoned
- 2004-12-13 RU RU2006124794/15A patent/RU2006124794A/ru not_active Application Discontinuation
- 2004-12-13 CA CA002548443A patent/CA2548443A1/en not_active Abandoned
- 2004-12-13 EP EP04816271A patent/EP1701720A1/de not_active Withdrawn
- 2004-12-13 JP JP2006543365A patent/JP2007513895A/ja not_active Withdrawn
- 2004-12-13 WO PCT/DE2004/002762 patent/WO2005056006A1/de active Application Filing
- 2004-12-13 ZA ZA200605706A patent/ZA200605706B/en unknown
- 2004-12-13 CN CNA2004800367053A patent/CN1889945A/zh active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2529860C2 (ru) * | 2009-01-30 | 2014-10-10 | Тояма Кемикал Ко., Лтд. | Производное n-ацилантраниловой кислоты или его соль |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007513895A (ja) | 2007-05-31 |
| EP1701720A1 (de) | 2006-09-20 |
| CN1889945A (zh) | 2007-01-03 |
| CA2548443A1 (en) | 2005-06-23 |
| DE10359829A1 (de) | 2005-07-21 |
| BRPI0417542A (pt) | 2007-03-27 |
| WO2005056006A1 (de) | 2005-06-23 |
| AU2004296131A2 (en) | 2005-06-23 |
| US20070099982A1 (en) | 2007-05-03 |
| AU2004296131A1 (en) | 2005-06-23 |
| ZA200605706B (en) | 2008-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI111717B (fi) | Menetelmä terapeuttisesti käyttökelpoisen 2-[(dimetyyliamino)metyyli]-1-(3-metoksifenyyli)sykloheksanoli-N-oksidin valmistamiseksi | |
| CZ285980B6 (cs) | Derivát dipeptidu L-prolin-L-ergininaldehyd a farmaceutický prostředek,který ho obsahuje | |
| EP0989131A4 (en) | THIENOTRIAZOLODIAZEPINE COMPOUNDS AND THEIR MEDICAL APPLICATIONS | |
| NZ512184A (en) | Aromatic heterocycle compounds having HIV integrase inhibiting activities | |
| WO2004113365A3 (en) | Hepatitis c serine protease tri-peptide inhibitors | |
| EP2341065A3 (en) | Inhibitors of serine proteases, particularly HCV NS3-NS4a protease | |
| WO2004058679A3 (en) | Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto | |
| MXPA06014417A (es) | Usos anti-virales de complejos de acido borinico. | |
| WO2003100009A2 (en) | Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof | |
| AU6972098A (en) | Peptidyl-2-amino-1-hydroxyalkanesulfonic acid cysteine protease inhibitors | |
| RU2006124794A (ru) | Применение цис-гидроксипролина в качестве ингибитора ключевых мишеней | |
| MY133527A (en) | Isoquinoline derivatives | |
| WO2005000353A1 (ja) | 血清コレステロール低下剤或はアテローム性動脈硬化症の予防又は治療剤 | |
| WO2005084685A2 (en) | Boronate medicaments suitable for short duration anticoagulation | |
| US4778798A (en) | Pharmaceutical compositions having vasodilating and antianoxic activities | |
| RU2009123401A (ru) | Фармацевтические композиции для лечения капиллярной артериопатии | |
| ES2606925T3 (es) | Compuesto de benzopirano deuterado y aplicación del mismo | |
| JP5117377B2 (ja) | 抗腫瘍化合物及びその医薬組成物 | |
| HRP20130959T1 (hr) | Antikancerozni spojevi i farmaceutski pripravci koji ih sadrže | |
| TW200500369A (en) | Cephem compounds | |
| KR101097189B1 (ko) | 디히드록시크로몬 유도체를 유효성분으로 함유하는 코로나바이러스로 인해 유발되는 질환의 치료 및 예방을 위한 약학 조성물 | |
| WO2005013935A3 (en) | Composition for releasing a weak base for an extended period of time | |
| AU2003230665A1 (en) | Substituted tetrahydroisoquinoline compounds, methods of making, and their use | |
| EP0109142A2 (en) | Peptide and pseudopeptide derivatives | |
| JP2520244B2 (ja) | 弗素化ジアミノアルキン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20090310 |